More than 350 million people are infected with Hepatitis B Virus (HBV) globally. The main aim of any chronic hepatitis B therapy is to prevent liver cirrhosis and its sequelae, including Hepatocellular Carcinoma (HCC). This is a cross sectional study that analysed medical records of 281 HBsAg seropositive patients in order to determine those factors that are associated with the reduction in the HBV viral load and the duration of HBV lamivudine monotherapy in order to attain a virological response.
